DDInter734 DDInter640
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Fidaxomicin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Amoxapine
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Fidaxomicin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Azithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Nafcillin
Nafcillin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Encorafenib
Fidaxomicin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Encorafenib
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Fidaxomicin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Fidaxomicin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Nafcillin (Compound) and Nafcillin may lead to a major life threatening interaction when taken with Encorafenib